TY - JOUR
T1 - Safety of Revascularization Deferral of Left Main Stenosis Based on Instantaneous Wave-Free Ratio Evaluation
AU - Warisawa, Takayuki
AU - Cook, Christopher M.
AU - Rajkumar, Christopher
AU - Howard, James P.
AU - Seligman, Henry
AU - Ahmad, Yousif
AU - El Hajj, Stephanie
AU - Doi, Shunichi
AU - Nakajima, Akihiro
AU - Nakayama, Masafumi
AU - Goto, Sonoka
AU - Vera-Urquiza, Rafael
AU - Sato, Takao
AU - Kikuta, Yuetsu
AU - Kawase, Yoshiaki
AU - Nishina, Hidetaka
AU - Petraco, Ricardo
AU - Al-Lamee, Rasha
AU - Nijjer, Sukhjinder
AU - Sen, Sayan
AU - Nakamura, Sunao
AU - Lerman, Amir
AU - Matsuo, Hitoshi
AU - Francis, Darrel P.
AU - Akashi, Yoshihiro J.
AU - Escaned, Javier
AU - Davies, Justin E.
N1 - Funding Information:
Dr. Warisawa has received consulting fees from Abbott Vascular and Philips. Dr. Cook has received speaker’s honoraria from Philips Volcano. Dr. Seligman has received a research grant from Amgen. Dr. Howard is supported by the Wellcome Trust (212183/Z/18/Z). Dr. Kikuta has received speaking fees from Abbott Vascular and Philips. Drs. Ahmad and Sen are supported by the Academy of Medical Sciences and Imperial Biomedical Research Centre. Dr. Sen is supported by the Medical Research Council (G1000357); and has served on the Speakers Bureaus and participated in educational events for Pfizer, Phillips, Daichi-Sankyo, and AstraZeneca; and has received speaking fees from Volcano, Pfizer, and Medtronic. Dr. Al-Lamee has received a speaking honorarium from Philips Volcano. Dr. Petraco has served as a consultant for and received speaking fees from Philips Volcano; and is supported by the British Heart Foundation (FS/11/46/28861). Dr. Nijjer has received travel support and speaking fees from Philips Volcano. Dr. Davies holds patents pertaining to the iFR technology; is a consultant for Philips Volcano; and has received research grants from Philips Volcano. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Publisher Copyright:
© 2020
PY - 2020/7/27
Y1 - 2020/7/27
N2 - Objectives: The aim of this study was to assess the long-term clinical outcomes of patients with left main coronary artery (LM) stenosis in whom treatment strategy was based on the instantaneous wave-free ratio (iFR). Background: The overall safety of iFR to guide revascularization decision making in patients with stable coronary artery disease has been established. However, no study has examined the safety of deferral of revascularization of LM disease on the basis of iFR. Methods: This multicenter observational study included 314 patients in whom LM stenosis was deferred (n = 163 [51.9%]) or revascularized (n = 151 [48.1%]) according to the iFR cutoff ≤0.89. The primary endpoint was a composite of all-cause death, nonfatal myocardial infarction, and ischemia-driven target lesion revascularization. The secondary endpoints were each individual component of the primary endpoint and also cardiac death. Results: At a median follow-up period of 30 months, the primary endpoint occurred in 15 patients (9.2%) in the deferred group and 22 patients (14.6%) in the revascularized group (hazard ratio: 1.45; 95% confidence interval: 0.75 to 2.81; p = 0.26), indicating no evidence of a significant difference between the 2 groups. For the secondary endpoints, findings in the iFR-based deferral and revascularization groups were as follows: all-cause death, 3.7% versus 4.6%; cardiac death, 1.2% versus 2.0%; nonfatal myocardial infarction, 2.5% versus 5.3%; and target lesion revascularization, 4.3% versus 5.3% (p > 0.05 for all). Conclusions: Deferral of revascularization of LM stenosis on the basis of iFR appears to be safe, with similar long-term outcomes to those in patients in whom LM revascularization was performed according to iFR values.
AB - Objectives: The aim of this study was to assess the long-term clinical outcomes of patients with left main coronary artery (LM) stenosis in whom treatment strategy was based on the instantaneous wave-free ratio (iFR). Background: The overall safety of iFR to guide revascularization decision making in patients with stable coronary artery disease has been established. However, no study has examined the safety of deferral of revascularization of LM disease on the basis of iFR. Methods: This multicenter observational study included 314 patients in whom LM stenosis was deferred (n = 163 [51.9%]) or revascularized (n = 151 [48.1%]) according to the iFR cutoff ≤0.89. The primary endpoint was a composite of all-cause death, nonfatal myocardial infarction, and ischemia-driven target lesion revascularization. The secondary endpoints were each individual component of the primary endpoint and also cardiac death. Results: At a median follow-up period of 30 months, the primary endpoint occurred in 15 patients (9.2%) in the deferred group and 22 patients (14.6%) in the revascularized group (hazard ratio: 1.45; 95% confidence interval: 0.75 to 2.81; p = 0.26), indicating no evidence of a significant difference between the 2 groups. For the secondary endpoints, findings in the iFR-based deferral and revascularization groups were as follows: all-cause death, 3.7% versus 4.6%; cardiac death, 1.2% versus 2.0%; nonfatal myocardial infarction, 2.5% versus 5.3%; and target lesion revascularization, 4.3% versus 5.3% (p > 0.05 for all). Conclusions: Deferral of revascularization of LM stenosis on the basis of iFR appears to be safe, with similar long-term outcomes to those in patients in whom LM revascularization was performed according to iFR values.
KW - coronary physiology
KW - left main coronary artery disease
KW - registry-based study
KW - resting intracoronary index
UR - http://www.scopus.com/inward/record.url?scp=85085333175&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085333175&partnerID=8YFLogxK
U2 - 10.1016/j.jcin.2020.02.035
DO - 10.1016/j.jcin.2020.02.035
M3 - Article
C2 - 32417088
AN - SCOPUS:85085333175
SN - 1936-8798
VL - 13
SP - 1655
EP - 1664
JO - JACC: Cardiovascular Interventions
JF - JACC: Cardiovascular Interventions
IS - 14
ER -